Approvals & regulatory · first seen 7h ago, updated 7h ago

FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’

1 outlet GLP-1 & obesity drugs Eli Lilly FDA

FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary conditions.”

Summary from BioSpace - All News.

Coverage 1 article · 1 outlet

BioSpace - All News 7h ago
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’